CellaVision (CEVI) Q1 2025 earnings summary

Executive summary

• Net sales reached SEK 195 million in Q1 2025, up 14.6% year-over-year, with 14.1% organic growth and strong contributions from all regions and product categories.

• EBITDA margin improved to 34% from 29% in Q1 2024, driven by price increases, favorable sales mix, and robust demand for instruments, software, and reagents.

• The company maintains a strong financial position with minimal debt, growing cash balance, and solid operational cash flow.

• Increased R&D investment supports ongoing clinical trials for bone marrow analysis and upgrades to hematology solutions.

• All regions contributed to growth: EMEA up 21%, Americas up 8%, and APAC up 12%.

Financial highlights

• Net sales rose 14.6% to SEK 195m in Q1 2025, with organic growth of 14.1%.

• Gross margin improved to 70% from 66% in Q1 2024, attributed to price increases and favorable product mix.

• EBITDA was SEK 66 million (34% margin), up from SEK 49 million (29%) in Q1 2024.

• Operating expenses were SEK 80 million (41% of revenue), with R&D spend at 22% of sales.

• Operating cash flow reached SEK 61 million, with total cash flow for the quarter at SEK 37 million.

Outlook and guidance

• Management remains optimistic about continued growth and long-term value creation, citing strong market signals and ongoing traction across regions and product lines.

• Gross margin is expected to remain around 70% for the remainder of the year, with some variability possible due to FX and other factors.

• Financial ambition targets a CAGR of 15%+ and EBITDA margin above 30% over the economic cycle.

• Price adjustments will continue, but future increases may be less significant than last year.

• Ongoing digitalization in diagnostics and strong demand in networked labs expected to support future growth.